Ionizable Cationic Lipid for Nucleic Acid Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for delivering therapeutic nucleic acids, such as mRNA, face challenges in achieving targeted intracellular delivery and stability, particularly in aqueous solutions, which can lead to side reactions and reduced efficacy.
Innovation Solution
A novel cationic lipid compound, specifically designed to form lipid nanoparticles that encapsulate and deliver therapeutic polyanions, including mRNA, using a composition that includes specific alkyl and aryl groups to enhance stability and targeted cellular uptake.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If therapeutic nucleic acids are delivered in aqueous solutions, then delivery to targeted cells is facilitated, but side reactions occur and stability is reduced
Solution Approach 1:
The patent uses anhydrous organic solvents or anhydrous polar aprotic solvents as intermediary media to dissolve therapeutic nucleic acids before encapsulation into lipid particles. This intermediary step prevents direct exposure to aqueous environments that cause degradation, while still enabling subsequent cellular delivery. The solvent acts as a bridge between the nucleic acid and the delivery system, maintaining stability during preparation and enabling effective delivery afterward.
2Quantity of substance
If conventional lipids are used for nucleic acid delivery, then encapsulation is achieved, but targeted intracellular delivery is limited
Solution Approach 1:
The patent modifies lipid molecules with specific functional groups at different locations to create heterogeneous structures with localized functions. The lipid composition includes cholesterol for membrane interaction, PEG-lipids for steric stabilization and extended circulation, and ionizable cationic lipids for nucleic acid complexation and endosomal escape. Each lipid component has specific local properties that collectively enable both encapsulation and targeted delivery to specific cell types and tissues.
3Ease of manufacture
If nucleic acids are exposed to polar aqueous solutions, then delivery is simplified, but side reactions occur reducing efficacy
Solution Approach 1:
The patent employs anhydrous polar aprotic solvents as an inert environment during the encapsulation process. These solvents do not promote hydrolysis or other water-dependent degradation reactions that would occur in aqueous solutions. The inert anhydrous environment protects the therapeutic nucleic acids from side reactions during formulation, while still allowing effective encapsulation into the lipid delivery system.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The novel cationic lipid composition effectively encapsulates nucleic acids, protecting them from degradation and facilitating targeted delivery to cells, including those in the liver, lung, kidney, brain, blood, spleen, or bone, with potential therapeutic applications in treating cancer, inflammatory diseases, and other disorders.
Implementation Method 1
A number of different types of nucleic acids are currently being developed as therapeutics... stable and has a long shelf-life... encapsulations of the nucleic acids
Implementation Method 2
The delivery of a therapeutic compound to a subject is important for its therapeutic effects and usually it can be impeded by limited ability of the compound to reach targeted cells and tissues
Data Source
Figure 1
Figure 2
Figure 3
AI summary
What is described is a compound of formula I wherein X is an ethene, or an unsubstitiited or substituted arene or heteroarene; Y is a bond, an ethene, or an unsubstituted or substituted arene or heteroarene; Z is S or O; L is a linear or branched alkylene of 1 to 6 carbons; R1 and R2 are independently a linear or branched alkyl or alkenyl of 1 to 18 carbons; R3 and R4 are independently a linear or branched alkyl of 1 to 6 carbons; n is 0 to 6; and m, p, q, and r are independently 1-18; or a pharmaceutically acceptable salt thereof.